A team of researchers in the United States has developed a new non-invasive strategy for treating a deadly type of brain cancer known as glioblastoma. The research team from Washington and Northwestern universities in Illinois successfully created nasal drops containing a type of amino acid that stimulates the body's immune system to target cancer. The researchers confirmed in statements to the scientific news portal 'SciTech Daily' that the new drug succeeded in laboratory tests on mice by stimulating the body's internal immune system to target tumors. Glioblastoma is the most common type of brain tumor in the United States, affecting three in every 100,000 people. This cancer spreads very quickly in a patient's brain and most often leads to the patient's death. Doctors say that one of the main reasons preventing the treatment of this cancer is the difficulty of delivering the drug into the brain. Dr. Alexander Stegh, a neurologist at Washington University and director of research in the brain tumor department at the Siteman Cancer Center, stated: 'We wanted to change this reality and develop non-invasive methods to activate the immune system to attack the cancer.' He added: 'Through this study, we succeeded in creating DNA nanostructures through genetic engineering that can stimulate a strong immune response inside the brain, redefining the pathways for cancer immunotherapy.'
